Company news
Ose Immunotherapeutics Sa (EURONEXT:OSE) news
Every Ose Immunotherapeutics Sa press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
OSE Immunotherapeutics Welcomes First Patient Dosed by Veloxis in the Phase 2 RENGEVITY-201 Trial Evaluating Pegrizeprument (VEL-101) for...
September 9, 2026
OSE Immunotherapeutics se félicite de l’inclusion du premier patient traité par Veloxis dans l’étude de phase 2 RENGEVITY-201 évaluant le...
September 8, 2026
Informations relatives au nombre total de droits de vote et d’actions composant le capital
September 6, 2026
OSE Immunotherapeutics to host a KOL webcast dedicated to lusvertikimab on September 2, 2026
August 27, 2026
Informations relatives au nombre total de droits de vote et d’actions composant le capital
August 25, 2026
Informations relatives au nombre total de droits de vote et d’actions composant le capital
July 7, 2026
OSE Immunotherapeutics Reports Results of its 2026 Annual General Meeting
June 24, 2026
Annual General Meeting on June 24, 2026 Procedures for obtaining preparatory documents for the General Meeting
June 3, 2026
OSE Immunotherapeutics Reports Full Year 2025 Audited Consolidated Financial Results and Announces the Filing of its 2025 Universal Regis...
June 3, 2026
OSE Immunotherapeutics to Implement a Flexible Bridge Equity Financing
May 28, 2026
OSE Immunotherapeutics Reports Positive Topline Results of TEDOVA Phase 2 Trial with Tedopi® in Recurrent Ovarian Cancer
May 22, 2026
OSE Immunotherapeutics Reports Full Year 2025 Unaudited Consolidated Financial Results and 2026 Q1 Cash Position
April 30, 2026
OSE Immunotherapeutics Welcomes FDA Orphan Drug Designation Granted to Pegrizeprument (VEL-101) for Prevention of Organ Rejection in Hear...
April 27, 2026
OSE Immunotherapeutics Announces Presentation of TEDOVA Phase 2 Topline Results of Tedopi® in Ovarian Cancer at the ASCO 2026 Meeting
April 23, 2026
OSE Immunotherapeutics to Present a Novel, First-in-Class, FPR2 Agonist Monoclonal Antibody in the Resolution of Chronic Inflammation at ...
April 15, 2026
OSE Immunotherapeutics Evolves its Leadership Team
April 14, 2026
OSE Immunotherapeutics to Present at Upcoming Investor Conferences
March 23, 2026
OSE Immunotherapeutics Announces its 2026 Financial Calendar
March 16, 2026
OSE Immunotherapeutics Confirms Marc Le Bozec as Chief Executive Officer to Lead Next Phase of Strategic Growth
March 10, 2026
OSE Immunotherapeutics Accelerates Strategic Refocusing to Advance Late Stage Value Drivers Lusvertikimab and Tedopi®
March 2, 2026
OSE Immunotherapeutics Receives Second Positive IDMC Recommendation for Phase 3 ARTEMIA Trial Evaluating Tedopi® in Non-Small Cell Lung C...
February 26, 2026
OSE Immunotherapeutics Selects Chronic Pouchitis and Hidradenitis Suppurativa as New Key Indications for Lusvertikimab
January 29, 2026
OSE Immunotherapeutics Welcomes FDA Orphan Drug Designation Granted to Pegrizeprument (VEL-101)
January 21, 2026
Half-Year Report on Liquidity Contract with Invest Securities
January 20, 2026
OSE Immunotherapeutics Unveils 2026–2028 Strategic Plan With Four Opportunities for Value Creation
December 9, 2025
OSE Immunotherapeutics Announces Strategic Amendment to AbbVie’s Partnership on ABBV-230 Development
December 8, 2025
OSE Immunotherapeutics Announces Positive Recommendation from Independent Data Monitoring Committee (IDMC) to Continue Pivotal Phase 3 AR...
November 17, 2025
OSE Immunotherapeutics Reports First Half 2025 Financial Results
October 15, 2025
Appointment of Marc Le Bozec as Interim CEO
October 3, 2025
Full renewal of the Board of Directors Election of Dr. Markus Cappel as Chairman of the Board of Directors
September 30, 2025
OSE Immunotherapeutics, Inserm Transfert and Nantes University Announce Strategic Partnership to Accelerate Innovation in Immunotherapy
September 26, 2025
OSE Immunotherapeutics publie sa position de trésorerie au 30 juin 2025
September 25, 2025
Correction of a Material Error Relating to the Total Number of Voting Rights and Shares Comprising the Share Capital
September 24, 2025
OSE Immunotherapeutics acknowledges the decision of the Nantes Commercial Court
September 23, 2025
Two International Proxy Advisory Firms Support the Governance Project Proposed by OSE Immunotherapeutics at the September 30th General Me...
September 22, 2025
Update on Information Relating to the General Meeting of September 30, 2025
September 12, 2025
OSE Immunotherapeutics and the FoRT Foundation Announce Completion of Enrollment in Combi-TED, a Phase 2 Clinical Trial Evaluating Tedopi...
September 11, 2025
OSE Immunotherapeutics Board Urges Support for Value-Driving Strategy and Open-Minded Governance - Publication of Circular for Combined A...
September 9, 2025
OSE Immunotherapeutics: A Clear Strategy, Balanced Governance, and a Firm Course toward Value Creation
September 4, 2025
OSE Immunotherapeutics Reaffirms its Strategic Priorities and Publishes Shareholder Q&A to Restore Information Ahead of AGM
August 29, 2025
OSE Immunotherapeutics Proposes Governance Evolution and Reaffirms Strategic Priorities ahead of Annual General Meeting
August 25, 2025
OSE Immunotherapeutics Appoints Thomas Gidoin as Chief Financial Officer
August 20, 2025
OSE Immunotherapeutics lance une Newsletter pour les investisseurs individuels
July 17, 2025
OSE Immunotherapeutics met à jour l’information sur les procédures en cours
July 2, 2025
OSE Immunotherapeutics Publishes Letter to Shareholders
June 30, 2025
OSE Immunotherapeutics provides an update on ongoing proceedings
June 25, 2025
OSE Immunotherapeutics Reaffirms Commitment to Holding a Transparent and Serene General Meeting in Compliance with Market Rules
June 20, 2025
ADJOURNMENT OF THE GENERAL MEETING INITALLY CONVENED ON JUNE 25, 2025
June 11, 2025
UPDATE ON THE TERMS OF THE SHAREHOLDERS GENERAL MEETING
June 9, 2025
Ose Immunotherapeutics : Documents made available to the shareholders for the combined general meeting of June 25th, 2025
June 4, 2025